You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 1, January 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Pediatrics
 •Pediatrics, Other
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Pediatric Dosing
 •Alert me on articles by topic

Intertriginous Eruption Associated With Chemotherapy in Pediatric Patients

Kathryn A. Webber, BA; Liborka Kos, MD; Kristen E. Holland, MD; David A. Margolis, MD; Beth A. Drolet, MD

Arch Dermatol. 2007;143(1):67-71.

Background  Cutaneous eruptions commonly occur in children receiving chemotherapy, and the clinical situation often demands immediate diagnosis and initiation of treatment. Several patterns of cutaneous eruptions to chemotherapy have been reported; however, the nomenclature used to describe these entities has been derived from the histologic findings. The morphologic characteristics, distribution, and natural history of these reactions have not been well established.

Observations  We report the clinical features of 16 pediatric patients with a distinctive chemotherapy-induced eruption. The eruption is most prominent in or limited to intertriginous regions and areas of occlusion. We were not able to identify any single chemotherapeutic agent or even a group of agents in the same pharmacologic family that seemed to be associated with this reaction. The eruption did not appear to be related to sex, age, ethnicity, underlying malignancy, or genetic disease.

Conclusions  Recognition of this distinct clinical pattern can help rule out more serious entities, avoid a biopsy, and reassure the physician and patient of the benign and self-resolving clinical course. This entity may be observed with many chemotherapeutic agents and underlying diseases, but most often with high-dose chemotherapy protocols.


Author Affiliations: Departments of Dermatology (Ms Webber and Drs Kos, Holland, and Drolet) and Pediatrics (Drs Margolis and Drolet), Medical College of Wisconsin, Milwaukee.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intertriginous Eruption Associated with Chemotherapy in Children
Journal Watch Dermatology 2007;2007:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.